Skip to main content
. Author manuscript; available in PMC: 2017 Apr 14.
Published in final edited form as: Leukemia. 2016 Oct 14;31(4):872–881. doi: 10.1038/leu.2016.282

Table 2.

Response Evaluation

Response n (%)
AML (n=37) CR/CRc 2 5%
CRi 2 5%
mLFS 7 19%
TF 26 70%
MDS (n=14) CR/CRc 2 5%
CRi 0 0%
mCR 4 11%
SD 2 5%
Failure 6 16%
HI-P, HI-N 1 3%

CR: Complete Remission; CRc: Cytogenetic CR; CRi: CR with incomplete blood count recovery; TF: Treatment failure; mLFS: Morphologic leukemia-free state; mCR: marrow CR; SD: stable disease; HI-P: Hematologic improvement-platelets; HI-N: Hematologic improvement-neutrophils